Company profile
Clever Leaves Holdings Inc.
OTC: CLVR · Healthcare · Drug Manufacturers - Specialty & Generic
#569 of 1,418 Healthcare companies by revenue38th-percentile growth
EA Score
——FH —DQ 41GM —SS 34
v0.1 · 25/100 weight · pillars only
↑ balance-sheet leverage, workforce scale · ↓ market scale, disclosure history
Methodology →Revenue TTM
$17.4M
Rev growth YoY (TTM)
+3.6%
Net income (FY)
-$17.9M
Employees
296
as of 2026-08-31
Market cap
$351
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$17.4M$17.4M2023
Net income-$17.9M-$17.9M2023
Operating income-$15.6M-$15.6M2023
Total assets$31.2M$31.2M2023
Liabilities$7.0M$7.0M2023
Equity$24.2M$24.2M2023
Revenue trend
FY2020 – FY2023 · USD
FY20
FY20
FY21
FY22
FY23
Revenue by segment
Filed disclosures · FY2023
By product
Non-Cannabinoid62%
Cannabinoid38%
By geography
UNITED STATES62%
BRAZIL18%
AUSTRALIA10%
Other Countries, Not Separately Disclosed5%
ISRAEL3%
GERMANY1%
The read
What is Clever Leaves Holdings Inc.’s revenue?
Clever Leaves Holdings Inc. booked $17.4M in FY2023 revenue, contracting 2.2% year over year — slower than 62% of Healthcare companies we track, at a -102.8% net margin.
Peers · Healthcare
Vibe Growth Corporation58CMicron Solutions, Inc.——Vivos Therapeutics, Inc.38DChoom Holdings Inc.——Veru Inc.49DPelthos Therapeutics Inc.37DNeighbors
Palm Beach →Key facts
CEOAndres Fajardo
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersBoca Raton, FL
ExchangeOTC: CLVR
Employees296
IPO date2020-12-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.